Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review.

ABSTRACT:

Introduction

Chronic kidney disease is a significant public health issue. Dapagliflozin has been shown to improve the quality of life for patients with chronic kidney disease. This review aimed to systematically assess the cost-effectiveness of adding dapagliflozin to standard care compared with standard care alone for treating chronic kidney disease.

Methods

The relevant studies were searched in PubMed, Web of Science, Scopus, Embase, and Cochrane from the inception date to June 1, 2024. The titles, abstracts, and full texts were independently evaluated and screened by two authors. Additionally, the economic evaluation studies were assessed independently by two authors using the consolidated health economic evaluation reporting standards checklist.

Results

14 studies

SUBMITTER: Wang L 

PROVIDER: S-EPMC11657770 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature